| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43fede5c7c17cae2fa22470dfb802d55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_99f247ba7ac31b12ede3c1eba20f8af2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_93c149a00c05495b3764c81c54f01118
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c06d114257182ee7efd4c696c5fdb836
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cef982a147702e832e1276419ec2a7c3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-111
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57449
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| filingDate |
2008-02-06^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_920c8740acb544ce28ad52df4d45d8e4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7819504f6ac05f2de0b52d74f895992e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b6a0f34dd224f8879179c24a77f4a891
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_391d220de4ee14eeb392e057835c018b |
| publicationDate |
2008-08-14^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2008098086-A2 |
| titleOfInvention |
A gene expression profile that predicts ovarian cancer subject response to chemotherapy |
| abstract |
A gene profiling signature is disclosed herein. The gene signature can predict whether a subject with ovarian cancer will be chemorefractory, chemoresistant or chemosensitive. Thus, methods are disclosed for determining whether a subject with ovarian cancer will be sensitive to treatment with a chemotherapeutic agent. Methods are also provided for increasing sensitivity to the chemotherapeutic agent if the presence of differential expression indicates that the ovarian cancer has a decreased sensitivity to chemotherapeutic agent. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013095793-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018508183-A |
| priorityDate |
2007-02-06^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |